{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:28:05Z","timestamp":1770348485932,"version":"3.49.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p>To date, the therapeutic use of cannabinoids in chronic pain management remains controversial owing to the limited clinical evidence found in randomized clinical trials (RCTs), the heterogeneous nature of the clinical indication, and the broad range of cannabis-based medicinal products (CBMPs) used in both experimental and observational clinical studies. Here we evaluate patient-reported clinical outcomes (PROMS) in a cohort of adult patients, diagnosed with chronic pain of diverse etiology, who received adjuvant treatment with oral, cannabis-based, magistral formulations between May and September 2021 at the Latin American Institute of Neurology and Nervous System (ILANS-Zerenia) in Bogot\u00e1, Colombia. During this period, 2,112 patients completed a PROMS questionnaire aimed at capturing the degree of clinical improvement of their primary symptom and any potential side effects. Most participants were female (76.1%) with an average age of 58.7 years old, and 92.5% (1,955 patients) reported some improvement in their primary symptom (<jats:italic>p<\/jats:italic> &amp;lt; 0.001). Two monovarietal, full-spectrum, cannabis formulations containing either cannabidiol (CBD 30 mg\/mL; THC &amp;lt;2 mg\/mL) or a balanced composition (THC 12 mg\/mL; CBD 14 mg\/mL) accounted for more than 99% of all prescriptions (59.5 and 39.8%, respectively). The degree of improvement was similar between both formulations, although males reported less effectiveness in the first 4 weeks of treatment. Sex-specific differences were also found in prescription patterns, with male patients increasing the intake of the balanced chemotype overtime. For many patients (71.7%) there were no adverse side effects associated to the treatment and those most reported were mild, such as somnolence (13.0%), dizziness (8.1%) and dry mouth (4.2%), which also appeared to fade over time. Our results constitute the first real-world evidence on the clinical use of medicinal cannabis in Colombia and suggest that cannabis-based oral magistral formulations represent a safe and efficacious adjuvant therapeutic option in the management of chronic pain.<\/jats:p>","DOI":"10.3389\/fpain.2022.854795","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:51:06Z","timestamp":1648518666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Sex-Dependent Prescription Patterns and Clinical Outcomes Associated With the Use of Two Oral Cannabis Formulations in the Multimodal Management of Chronic Pain Patients in Colombia"],"prefix":"10.3389","volume":"3","author":[{"given":"Guillermo","family":"Moreno-Sanz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Madiedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janosch","family":"Kratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oier","family":"Aizpurua-Olaizola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R. D.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan R.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Pati\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredy O.","family":"Mendivelso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/cbdv.200790144","article-title":"History of cannabis and its preparations in saga, science, and sobriquet","volume":"4","author":"Russo","year":"2007","journal-title":"Chem Biodiversity."},{"key":"B2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tips.2016.12.002","article-title":"Modern history of medical cannabis: from widespread use to prohibitionism and back","volume":"38","author":"Pisanti","year":"2017","journal-title":"Trends Pharmacol Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/head.12570","article-title":"Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long, strange trip it's been","volume":"55","author":"Baron","year":"2015","journal-title":"Headache."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14020078","article-title":"Clinical evidence of magistral preparations based on medicinal cannabis","volume":"14","author":"Arias","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1021\/ja01858a058","article-title":"Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota Wild Hemp. I","volume":"62","author":"Adams","year":"1940","journal-title":"J Am Chem Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1021\/ja01865a508","article-title":"Conversion of cannabidiol to a product with marihuana activity. A type reaction for synthesis of analogous substances. Conversion of cannabidiol to cannabinol","volume":"62","author":"Adams","year":"1940","journal-title":"J Am Chem Soc."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1021\/ja01062a046","article-title":"Isolation, structure, and partial synthesis of an active constituent of Hashish","volume":"86","author":"Gaoni","year":"1964","journal-title":"J Am Chem Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/0040-4020(63)85022-X","article-title":"Hashish. I. The structure of cannabidiol","volume":"19","author":"Mechoulam","year":"1963","journal-title":"Tetrahedron."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc Natl Acad Sci USA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat Rev Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-21737-2_1","article-title":"Endocannabinoid system components: overview and tissue distribution","volume":"1162","author":"Joshi","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","article-title":"The cannabinoid system and pain","volume":"124","author":"Woodhams","year":"2017","journal-title":"Neuropharmacology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-3-030-21737-2_8","article-title":"Pharmacology of medical cannabis","volume":"1162","author":"Amin","year":"2019","journal-title":"Adv Exp Med Biol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","article-title":"Practical considerations in medical cannabis administration and dosing","volume":"49","author":"MacCallum","year":"2018","journal-title":"Eur J Int Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1377\/hlthaff.2018.05266","article-title":"Qualifying conditions of medical cannabis license holders in The United States","volume":"38","author":"Boehnke","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11481-021-10010-x","article-title":"The role of cannabis, cannabidiol and other cannabinoids in chronic pain. The perspective of physicians","author":"K\u00f6stenberger","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"J Am Med Assoc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.17245\/jdapm.2021.21.6.479","article-title":"Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis","volume":"21","author":"Sainsbury","year":"2021","journal-title":"J Dental Anesth Pain Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"CD012182","DOI":"10.1002\/14651858.CD012182.pub2","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"3","author":"M\u00fccke","year":"2018","journal-title":"Cochr Database Syst Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1097\/j.pain.0000000000001293","article-title":"Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies","volume":"159","author":"Stockings","year":"2018","journal-title":"Pain."},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","article-title":"Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain","volume":"39","author":"Johnson","year":"2010","journal-title":"J Pain Symptom Manage."},{"key":"B22","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of THC\/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis","volume":"260","author":"Langford","year":"2013","journal-title":"J Neurol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1517\/14656566.2014.918102","article-title":"Dronabinol and chronic pain: importance of mechanistic considerations","volume":"15","author":"De Vries","year":"2014","journal-title":"Exp Opin Pharmacother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000481089","article-title":"Dronabinol is a safe long-term treatment option for neuropathic pain patients","volume":"78","author":"Schimrigk","year":"2017","journal-title":"Eur Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"118","DOI":"10.7326\/M18-2972","article-title":"Brief commentary: cannabinoid dosing for chronic pain management","volume":"170","author":"Boehnke","year":"2019","journal-title":"Ann Intern Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","article-title":"Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process","volume":"3","author":"Bhaskar","year":"2021","journal-title":"J Cannabis Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s42238-021-00074-0","article-title":"A cannabis oracle? Delphi method not a substitute for randomized controlled trials of cannabinoids as therapeutics","volume":"3","author":"Hill","year":"2021","journal-title":"J Cannabis Res."},{"key":"B28","first-page":"303","article-title":"Correlation of single assessment numeric evaluation (SANE) with other patient reported outcome measures (PROMs)","volume":"7","author":"O'Connor","year":"2019","journal-title":"Arch Bone Joint Surg."},{"key":"B29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","article-title":"Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects","volume":"76","author":"Zuardi","year":"1982","journal-title":"Psychopharmacology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40266-021-00913-y","article-title":"Medical cannabis use among older adults in Canada: self-reported data on types and amount used, perceived effects","volume":"39","author":"Tumati","year":"2021","journal-title":"Drugs Aging"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21228870","article-title":"Cannabidiol for pain treatment: focus on pharmacology and mechanism of action","volume":"21","author":"Mlost","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.bpa.2020.06.004","article-title":"Use of cannabidiol (CBD) for the treatment of chronic pain","volume":"34","author":"Urits","year":"2020","journal-title":"Best Pract Res Clin Anaesthesiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.36076\/ppj.2018.1.E79","article-title":"The perils of overestimating the efficacy of cannabis-based medicines for chronic pain management","volume":"21","author":"H\u00e4user","year":"2018","journal-title":"Pain Phys."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000465","article-title":"The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy adults: a balanced placebo design trial","author":"De Vita","year":"2021","journal-title":"Exp Clin Psychopharmacol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00213-021-05823-w","article-title":"Evaluating cannabidiol (CBD) expectancy effects on acute stress and anxiety in healthy adults: a randomized crossover study","volume":"238","author":"Spinella","year":"2021","journal-title":"Psychopharmacology."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.pain.2013.12.007","article-title":"Placebo analgesia: clinical applications","volume":"155","author":"Klinger","year":"2014","journal-title":"Pain."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","article-title":"Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness","volume":"45","author":"McLean","year":"2011","journal-title":"J Psychiatr Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1037\/pha0000435","article-title":"No pain, all gain? Interim analyses from a longitudinal, observational study examining the impact of medical cannabis treatment on chronic pain and related symptoms","volume":"29","author":"Gruber","year":"2021","journal-title":"Exp Clin Psychopharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA."},{"key":"B40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00213-011-2495-x","article-title":"Interaction between cannabidiol (CBD) and \u0394(9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids","volume":"219","author":"Zuardi","year":"2012","journal-title":"Psychopharmacology."},{"key":"B41","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Multiple Scler."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002463","article-title":"Sex differences in medical cannabis-related adverse effects","author":"Aviram","year":"2021","journal-title":"Pain."}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2022.854795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:51:14Z","timestamp":1648518674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2022.854795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":42,"alternative-id":["10.3389\/fpain.2022.854795"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2022.854795","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,24]]},"article-number":"854795"}}